Hainan Poly Pharm Co Ltd - Asset Resilience Ratio

Latest as of June 2023: 2.33%

Hainan Poly Pharm Co Ltd (300630) has an Asset Resilience Ratio of 2.33% as of June 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read 300630 total debt and obligations for a breakdown of total debt and financial obligations.

Liquid Assets

CN¥146.93 Million

≈ $21.50 Million USD Cash + Short-term Investments

Total Assets

CN¥6.30 Billion

≈ $921.84 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2020–2022)

This chart shows how Hainan Poly Pharm Co Ltd's Asset Resilience Ratio has changed over time. See 300630 book value for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Hainan Poly Pharm Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is Hainan Poly Pharm Co Ltd worth.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	CN¥0.00	0%
Short-term Investments	CN¥146.93 Million	2.33%
Total Liquid Assets	CN¥146.93 Million	2.33%

Asset Resilience Insights

Limited Liquidity: Hainan Poly Pharm Co Ltd maintains only 2.33% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Hainan Poly Pharm Co Ltd Industry Peers by Asset Resilience Ratio

Compare Hainan Poly Pharm Co Ltd's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Takeda Pharmaceutical Co Ltd ADR NYSE:TAK	Drug Manufacturers - Specialty & Generic	4.94%
Regencell Bioscience Holdings Ltd NASDAQ:RGC	Drug Manufacturers - Specialty & Generic	43.05%
Changchun High & New Technology Industries Group Inc SHE:000661	Drug Manufacturers - Specialty & Generic	3.73%
Yuhan Corp. KO:000100	Drug Manufacturers - Specialty & Generic	0.99%
Tonghua Dongbao Pharmaceutical Co Ltd SHG:600867	Drug Manufacturers - Specialty & Generic	1.96%
Shandong Buchang Pharmaceuticals Co Ltd SHG:603858	Drug Manufacturers - Specialty & Generic	3.47%
Guangdong Zhongsheng Pharmaceutical Co Ltd SHE:002317	Drug Manufacturers - Specialty & Generic	6.62%
Guobang Pharma Ltd SHG:605507	Drug Manufacturers - Specialty & Generic	8.47%

Annual Asset Resilience Ratio for Hainan Poly Pharm Co Ltd (2020–2022)

The table below shows the annual Asset Resilience Ratio data for Hainan Poly Pharm Co Ltd.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2022-12-31	0.01%	CN¥455.91K ≈ $66.71K	CN¥5.96 Billion ≈ $871.99 Million	-1.51pp
2021-12-31	1.51%	CN¥70.55 Million ≈ $10.32 Million	CN¥4.66 Billion ≈ $682.23 Million	+1.50pp
2020-12-31	0.02%	CN¥550.35K ≈ $80.53K	CN¥3.06 Billion ≈ $447.19 Million	--

pp = percentage points

About Hainan Poly Pharm Co Ltd

SHE:300630 China Drug Manufacturers - Specialty & Generic

Market Cap

$73.10 Million

CN¥499.57 Million CNY

Market Cap Rank

#20408 Global

#4699 in China

Share Price

CN¥0.89

Change (1 day)

+1.14%

52-Week Range

CN¥0.69 - CN¥0.90

All Time High

CN¥70.54